Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
KRYS
#1037
Krystal Biotech, Inc. Common Stock
270.000
0
USD
+0.97%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.97%
Monthly Change
+7.24%
6 month change
+44.28%
Year Change
+44.28%
Previous Close
267.410
0
Open
270.000
0
Bid
Ask
Low
270.000
0
High
270.000
0
Volume
52
Markets
US Stock Market
Healthcare
KRYS
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
22.19 M
25.21 M
25.76 M
28.29 M
28.81 M
29.23 M
—
Valuation ratios
Enterprise value
1.06 B
1.42 B
1.88 B
3.18 B
4.17 B
6.71 B
19.96 B
Price to earnings ratio
—
-22.35
-14.43
320.41
52.22
36.04
133.59
Price to sales ratio
—
—
-28.05 K
68.4
16.04
18.98
60.59
Price to cash flow ratio
—
-32.39
-20.08
-39.05
37.75
36.76
126.42
Price to book ratio
—
2.62
3.87
4.45
4.92
6.05
9.87
Enterprise value to EBITDA ratio
-34.1
-21.71
-13.31
-29.97
58.16
40.18
136.91
Profitability ratios
Return on assets %
-0.1
-0.11
-0.25
0.01
0.08
0.15
0.17
Return on equity %
-0.11
-0.12
-0.27
0.01
0.09
0.17
0.19
Return on invested capital %
-411.43
-220.38
-293.7
-156.2
67.23
147.22
148.92
Gross margin %
100
—
100
100
100
100
400
Operating margin %
100 K
—
201.66 K
-216.43
22.61
41.45
165.75
EBITDA margin %
94.49 K
—
196.13 K
-209.07
24.67
42.92
171.64
Net margin %
97.48 K
—
194.41 K
21.56
30.69
52.64
209.57
Liquidity ratios
Quick ratio
—
—
—
17.55
7.02
9.56
37.88
Current ratio
17.8
17.18
13.3
17.76
7.28
9.95
39.42
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
-0
0
-0
0.07
0.31
0.33
0.34
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-2.16
-3.95
-3.2
4.15
6.71
6.73
EBIT per share
—
-3.08
-5.7
-3.95
2.21
5.39
5.4
EBITDA per share
—
-2.95
-5.54
-3.82
2.41
5.58
5.59
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
19.74
14.88
19.18
20.09
27.64
95.72
Net current asset value per share
—
19.92
15.06
21.18
24.95
34.21
119.19
Tangible book value per share
—
26.74
20.49
28.06
31.82
40.72
146.81
Working capital per share
—
18.77
13.92
19.99
21.52
30.77
107.11
Book value per share
—
26.74
20.49
28.06
31.82
40.72
146.81
News
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
Krishnan Krish S, president of Krystal Biotech, sells $6.58 million in KRYS stock
Krystal Biotech director Krishnan sells $6.58 million in shares
Krystal Biotech at TD Cowen Conference: Strategic Growth and Challenges
Daniel Janney sells Krystal Biotech (KRYS) shares worth $3.25 million
Krystal Biotech director Janney sells shares worth $10.1 million
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million
AI Play SPX Leads 17 Top Performers Onto Best Stock Screens Like IBD 50, Stock Spotlight, More
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark